

Code	Name	Partner	Disease domain	Mode of action	Current Phase / (Expected) Start date	(Expected) Completion date	Remarks
GLPG0187			Bonecancer	Integrin receptor antagonist			Stopped after Phase 1
GLPG0259		Janssen	RA (Rheumatoid Arthritis)	MAPKAPK5 inhibitor			Stopped after Phase 2
GLPG03xx			Undisclosed indication				Stopped Preclinical
GLPG0492			MD (Muscular Dystrophy)	Androgen receptor modulator			Stopped after Phase 1
GLPG0555		Before Glaxo SmithKline	OA (Osteoarthritis)	JAK1 inhibitor	Phase 1		Backup of GLPG0778
GLPG0634	Filgotinib/ Jyseleca	Gilead (Before AbbVie)	RA (Rheumatoid Arthritis)	JAK1 inhibitor	Phase 3 (FINCH 4)	Expected May '25	Approved in Europe, Japan
		Gilead (Before AbbVie)	UC (Ulcerative Colitis)	JAK1 inhibitor	Phase 3 (SELECTION 1)	Completed May '20	JAP Filing 1H21, EU App 2h21
		Gilead (Before AbbVie)	CD (Crohn's Disease)	JAK1 inhibitor	Phase 3 (DIVERSITY 1)	Expected Nov '21	
		Gilead (Before AbbVie)	Small bowel CD (Crohn's Disease)	JAK1 inhibitor	Phase 2	Completed July '20	
		Gilead (Before AbbVie)	Perianal Fistulizing CD (Crohn's Disease)	JAK1 inhibitor	Phase 2 (DIVERGENCE 2)	Completed Jan '21	
		Gilead (Before AbbVie)	SS (Sjogren Syndrome)	JAK1 inhibitor	Phase 2	Completed	
		Gilead (Before AbbVie)	AS (Ankylosing Spondylitis) (Bechterew)	JAK1 inhibitor	Phase 3 (SEALION 1, 2)	Expected July '24	
		Gilead (Before AbbVie)	PsA (Psoriatic Arthritis)	JAK1 inhibitor	Phase 3 (PENGUIN 1,2)	Expected Oct '21 and May '22	
		Gilead (Before AbbVie)	CLE (Cutaneous Lupus Erythematosus)	JAK1 inhibitor	Phase 2	Completed Dec '19	
		Gilead (Before AbbVie)	LMN (Lupus Membranous Nephropathy)	JAK1 inhibitor	Phase 2	Completed Feb '20	
		Gilead (Before AbbVie)	Uveitis	JAK1 inhibitor	Phase 2 (HUMBOLDT)	Expected July '22	
GLPG0778		Glaxo SmithKline	Lupus, Psoriasis, UC	JAK1 inhibitor			Stopped after Phase 2a
GLPG08xx			Undisclosed indication				Stopped Preclinical
GLPG0974		Before Glaxo SmithKline	IBD (Inflammatory Bowel Disease)	GPR43 inhibitor / FFAR2			Stopped after Phase 2
GLPG10xx			Undisclosed indication				Stopped Preclinical
GLPG1179		Before Glaxo SmithKline	Undisclosed indication				Stopped Preclinical
GLPG1205		Before Janssen	IPF (Idiopathic Pulmonary Fibrosis)	GPR84 inhibitor / FFA22R	Phase 2b / Expected start in 2021		Phase 2 (PNTA), Aug '20 completed
GLPG1332		Before Servier	OA (Osteoarthritis)	Antibioticum			Stopped Preclinical
GLPG1492			MRSA				Stopped Preclinical
GLPG1577		Before Glaxo SmithKline	Undisclosed indication				Stopped Preclinical
GLPG1690	Ziritaxestat	Before Janssen	IPF (Idiopathic Pulmonary Fibrosis)	Autotaxin inhibitor	Phase 3 (ISABELA)		Stopped due to unfavorable balance between safety and efficacy
			SC (Systemic Sclerosis, Scleroderma)	Autotaxin inhibitor	Phase 2 (NOVESA)		Stopped due to unfavorable balance between safety and efficacy
GLPG1790			Triple Negative Breastcancer	Ephrin Receptor Tyrosine Kinase inhibitor			Stopped Preclinical
GLPG1837		AbbVie	CF (Cystic Fibrosis)	1e potentiator			Continue with GLPG2451
GLPG1972		Servier	OA (Osteoarthritis)	ADAMTS-5 inhibitor	Phase 2 (ROCELLA) Aug '18	Completed Dec '20	Stopped due to lack of efficacy
GLPG20xx			Undisclosed indication				Stopped Preclinical
GLPG2196		Before Janssen	COPD (Chronic Obstructive Pulmonary Disease)	GPR84 antagonist/CFTR Potentiator			Backup of GLPG1205. Stopped Preclinical
GLPG2222		AbbVie	CF (Cystic Fibrosis)	1e C1 corrector			Sold to AbbVie
GLPG2384		Before Janssen	Undisclosed indication	GPR84 antagonist	Preclinical		Backup of GLPG1205, Still active?
GLPG2451		AbbVie	CF (Cystic Fibrosis)	2e potentiator			Sold to AbbVie
GLPG2534			AD (Atopic Dermatitis)		Preclinical		Still active?
GLPG2665		AbbVie	CF (Cystic Fibrosis)	1e C2 corrector			Stopped, Continue with GLPG2737
GLPG2737		Before AbbVie	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	2e C2 corrector	Phase 2, Nov '20 (Recruiting)	Expected Nov '22	Rights outside CF for GLPG_PCKD same as ADPKD?
GLPG2851		AbbVie	CF (Cystic Fibrosis)	2e C1 corrector			Sold to AbbVie
GLPG2938			IPF (Idiopathic Pulmonary Fibrosis)				Stopped Preclinical, Continue with GLPG3499
GLPG3067		AbbVie	CF (Cystic Fibrosis)	3e potentiator			Sold to AbbVie
GLPG3121		Gilead	Inflammation	JAK1/TYK2 inhibitor	Phase 1, April '21	Expected Nov '21	Previous Phase 1 stopped due to lack of PK effect. Now modified re
GLPG3211		AbbVie	CF (Cystic Fibrosis)	3e C2 corrector			Stopped, Continue with GLPG3748
GLPG3312	Toledo	Gilead	IBD (Inflammatory Bowel Disease)	SIK1/2/3 inhibitor	Phase 1, Jan '19	Completed Mar '20	Gen 1 Toledo, Phase 2 PoC expected in 2020
GLPG3499			IPF (Idiopathic Pulmonary Fibrosis)		Stopped in IPF preclinical		Still active?
GLPG3535		Before Calchan	Fibrosis		Preclinical		
GLPG3667		Gilead	Plaque Psoriasis	TYK2	Phase 1, Oct '20 (Recruiting)	Expected May '21	Planned Phase 2 in PSA and UC in H2 '21
GLPG3748		AbbVie	CF (Cystic Fibrosis)	4e C2 corrector			Sold to AbbVie
GLPG3808			Undisclosed indication		Preclinical		
GLPG3970	Toledo		Psoriasis	SIK2/3 inhibitor	Phase 1 (CALOSOMA)		Gen 2 Toledo (More selective)
			UC (Ulcerative Colitis)	SIK2/3 inhibitor	Phase 2 (SEA TURTLE), Oct '20 (Recruiting)	Expected Jun '21	Gen 2 Toledo (More selective)
			RA (Rheumatoid Arthritis)	SIK2/3 inhibitor	Phase 2 (LADIVUE), Oct '21 (Act. not recr)	Expected April '21	Gen 2 Toledo (More selective)
			SS (Sjogren Syndrome)	SIK2/3 inhibitor	Phase 2 (GLIDER), Jan '21 (Recruiting)	Expected May '22	Gen 2 Toledo (More selective)
			SLE (Systemic Lupus Erythematosus)	SIK2/3 inhibitor	Phase 1 (TAPINOMA), Dec '20	Expected Mar '22	Gen 2 Toledo (More selective)
GLPG4059			Diabetes Type 2	Novel MOA that does not hit triglycerides,	Phase 1, Sept '20 (Recruiting)	Expected Apr '21	No more priority therapeutic area
GLPG4124		Gilead	Fibrosis		Preclinical		
GLPG4259		Gilead	Inflammation				Backup for inflammation
GLPG4399	Toledo		RA (Rheumatoid Arthritis)	SIK3 inhibitor	Phase 1, Nov '20 (Recruiting)	Expected July '21	Gen 3 Toledo (More selective)
GLPG4471		Gilead	Inflammation				Backup of? Disease?
GLPG4586	#FIB56	Fibrocor	Fibrosis		Preclinical		
GLPG4605	Toledo		Fibrosis	SIK2/3 inhibitor			Gen 2 Toledo (More selective)
GLPG4716	#OATD-01	OncoArendi	IPF (Idiopathic Pulmonary Fibrosis), Sarcoidosis, Asthma	Gliptase inhibitor	Phase 1	Completed	Preparing Phase 2b (~200 patients)
GLPG4876	Toledo		IPF (Idiopathic Pulmonary Fibrosis)	SIK2/3 inhibitor			Stopped after Phase 2 (IGUANA) (GECKO)
MOR106	MorphoSys and Novartis		Atopic Dermatitis	IL-17C			Stopped after Phase 2 (IGUANA) (GECKO)
THR-687	Oxurion		DME (Diabetic Macular Edema)	Pan RGD integrin antagonist	Phase 1, Sept '18	Completed Nov '19	Phase 2 planned for mid 2021

Legend

XXX Stopped
 XXX Active

Disease domains

XXX Fibrosis
 XXX Inflammation
 XXX Osteoarthritis
 XXX Cancer
 XXX Other, Undisclosed or Unknown

Version 5, May 2021